The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats
Authors:
- T.K. GravesTGT.K. Graves
- S. GilorSGS. Gilor
- 1 July 2011
- journal article
- research article
- Published by Elsevier in Domestic Animal Endocrinology
- Vol. 41 (1) , 42-49
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Pharmacodynamics of Insulin Detemir and Insulin Glargine Assessed by an Isoglycemic Clamp Method in Healthy CatsJournal of Veterinary Internal Medicine, 2010
- Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous systemAmerican Journal of Physiology-Endocrinology and Metabolism, 2010
- The Role of Incretins in Glucose Homeostasis and Diabetes TreatmentPharmacological Reviews, 2008
- Expression of the GLP-1 Receptor in Mouse, Rat, and Human PancreasJournal of Histochemistry & Cytochemistry, 2008
- Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysisCurrent Medical Research and Opinion, 2008
- Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trialClinical Therapeutics, 2007
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- The Recombinant Rat Glucagon-Like Peptide-1 Receptor, Expressed in an α-Cell Line, Is Coupled to Adenylyl Cyclase Activation and Intracellular Calcium ReleaseExperimental and Clinical Endocrinology & Diabetes, 2005
- Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2001
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.Journal of Clinical Investigation, 1993